U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H25NO2
Molecular Weight 263.3758
Optical Activity ( + )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRAMADOL, (+)-

SMILES

CN(C)C[C@@]1([H])CCCC[C@@]1(c2cccc(c2)OC)O

InChI

InChIKey=TVYLLZQTGLZFBW-ZBFHGGJFSA-N
InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1

HIDE SMILES / InChI

Molecular Formula C16H25NO2
Molecular Weight 263.3758
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.drugs.com/tramadol.html | https://www.drugbank.ca/drugs/DB00193 | http://reference.medscape.com/drug/ultram-er-tramadol-343324 |

Tramadol (sold under the brand name Ultram) is a narcotic analgesic proposed for moderate to severe pain. Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. The analgesic properties of Tramadol can be attributed to norepinephrine and serotonin reuptake blockade in the CNS, which inhibits pain transmission in the spinal cord. The (+) enantiomer has the higher affinity for the OP3 receptor and preferentially inhibits serotonin uptake and enhances serotonin release. The (-) enantiomer preferentially inhibits norepinephrine reuptake by stimulating alpha(2)-adrenergic receptors. Tramadol is used primarily to treat mild-severe pain, both acute and chronic. Its analgesic effects take about one hour to come into effect and 2 h to 4 h to peak after oral administration with an immediate-release formulation. On a dose-by-dose basis, tramadol has about one-tenth the potency of morphine and is approximately equally potent when compared to pethidine and codeine. The most common adverse effects of tramadol include nausea, dizziness, dry mouth, indigestion, abdominal pain, vertigo, vomiting, constipation, drowsiness, and headache. Compared to other opioids, respiratory depression and constipation are considered less of a problem with tramadol.

Originator

Sources: Oyo Yakuri (1973), 7, (7), 1087-95.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1300.0 nM [EC50]
14.0 nM [Ki]
9.4 nM [Ki]
1493.0 nM [IC50]
3861.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ULTRAM

Approved Use

Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Launch Date

7.9418878E11
Primary
ULTRAM

Approved Use

Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Launch Date

7.9418878E11
Primary
ULTRAM

Approved Use

Tramadol hydrochloride extended-release tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Launch Date

7.9418878E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
332 ng/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
70 ng/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
O-DESMETHYLTRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5678 ng × h/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1319 ng × h/mL
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
O-DESMETHYLTRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
200 mg 1 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TRAMADOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (75%)
Vomiting (50%)
Headache (25%)
Dizziness postural (25%)
Vertigo (25%)
Dizziness (12.5%)
Pruritus (37.5%)
Decreased appetite (25%)
Hot flush (12.5%)
Sources:
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Other AEs: Seizure, Nausea and vomiting...
Other AEs:
Seizure (14.5%)
Nausea and vomiting (53.5%)
Tachycardia (4.8%)
Hypertension (mild, 38.4%)
Arrhythmia (5.3%)
Sources:
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Other AEs: Dry mouth, Sweating...
Other AEs:
Dry mouth (13.1%)
Sweating (6.7%)
Asthenia (8.6%)
Pruritus (7.3%)
Arthralgia (5%)
Headache (19%)
Nausea (25.1%)
Somnolence (16.1%)
Dizziness (13.6%)
Constipation (21.3%)
Vomiting (9.3%)
Anorexia (5.7%)
Insomnia (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 12.5%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Hot flush 12.5%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Decreased appetite 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Dizziness postural 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Headache 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Vertigo 25%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Pruritus 37.5%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Vomiting 50%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Nausea 75%
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 28
n = 8
Health Status: healthy
Age Group: 28
Sex: M+F
Population Size: 8
Sources:
Seizure 14.5%
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Tachycardia 4.8%
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Arrhythmia 5.3%
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Nausea and vomiting 53.5%
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Hypertension mild, 38.4%
1500 mg single, oral (median)
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 41
n = 359
Health Status: unknown
Age Group: 41
Sex: M+F
Population Size: 359
Sources:
Dry mouth 13.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Dizziness 13.6%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Somnolence 16.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Headache 19%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Constipation 21.3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Nausea 25.1%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Arthralgia 5%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Insomnia 5%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Anorexia 5.7%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Sweating 6.7%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Pruritus 7.3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Asthenia 8.6%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Vomiting 9.3%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy, adult
n = 1054
Health Status: unhealthy
Condition: osteoarthritis
Age Group: adult
Population Size: 1054
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
unlikely
yes
yes
likely (co-administration study)
Comment: Coadministration of quinidine, a selective inhibitor of CYP2D6, with tramadol ER resulted in a 50­ 60% increase in tramadol exposure; pharmacogenomic studies were also conducted: rapid conversion to active metabolite results in higher than expected serum M1 levels. Individuals who are ultra-rapid metabolizers should not use drug.
Page: 5.0
yes
likely (co-administration study)
Comment: The concomitant use of ULTRAM with cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine, and phenytoin, may result in an increase in tramadol plasma concentrations; Concomitant administration of tramadol immediate-release tablets with cimetidine, a weak CPY3A4 inhibitor, does not result in clinically significant changes in tramadol pharmacokinetics;
Page: 5.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
WHO Expert Committee on Drug Dependence. Thirty-second report.
2001
Interactions between systemic analgesics.
2001
Control of non-malignant chronic pain conditions in Japan and the possible future role of tramadol.
2001
Postanaesthetic shivering: epidemiology, pathophysiology, and approaches to prevention and management.
2001
Single-dose dipyrone for acute postoperative pain.
2001
Use of remifentanil in combination with desflurane or propofol for ambulatory oral surgery.
2001
Analgesic efficacy of tramadol 2 mg kg(-1) for paediatric day-case adenoidectomy.
2001 Apr
Pharmacology of oral combination analgesics: rational therapy for pain.
2001 Aug
Validation of a high-performance liquid chromatography method for tramadol and o-desmethyltramadol in human plasma using solid-phase extraction.
2001 Aug 15
Nefopam reduces thermal hypersensitivity in acute and postoperative pain models in the rat.
2001 Dec
Analgesic efficacy of tramadol if coadministered with ondansetron.
2001 Dec
Plasma glucose-lowering effect of tramadol in streptozotocin-induced diabetic rats.
2001 Dec
Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects.
2001 Jan
Investigation of racial variations in the metabolism of tramadol.
2001 Jan-Jun
Association of Dental Anaesthetists. Summer Scientific Meeting Stirling, Scotland 8-9 June, 2001. ADA meeting report.
2001 Jul
Metabolism of the analgesic drug, tramadol hydrochloride, in rat and dog.
2001 Jul
[Chronic pain in geriatrics].
2001 Jun
Role of tramadol in reducing pain on propofol injection.
2001 May
NSAIDS, COX-2 inhibitors and tramadol: acute postoperative pain management in day-case surgery patients.
2001 May
A comparison of tramadol, amitriptyline, and meperidine for postepidural anesthetic shivering in parturients.
2001 Nov
Gas chromatographic method using nitrogen-phosphorus detection for the measurement of tramadol and its O-desmethyl metabolite in plasma and brain tissue of mice and rats.
2001 Nov 5
Acetaminophen, aspirin, or Ibuprofen in combination analgesic products.
2001 Nov-Dec
Distribution of enantiomers of trans-tramadol and trans-O-demethyltramadol in central nervous system of rats.
2001 Oct
Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes expressing cloned M1 receptors.
2001 Oct
Ketorolac vs tramadol in the treatment of postoperative pain during maxillofacial surgery.
2001 Sep
Multidimensional on-line solid-phase extraction (SPE) using restricted access materials (RAM) in combination with molecular imprinted polymers (MIP).
2001 Sep
Intravenous regional anaesthesia using lignocaine and tramadol.
2001 Sep
Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial.
2001 Sep
Managing postoperative pain.
2001 Sep
Effects of chronic tramadol on pre- and post-synaptic measures of monoamine function.
2001 Sep
[Non-opioid analgesics in cancer pain].
2001 Sep
Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate.
2001 Sep
Psychosomatic reactions to a stressful environment and an attempt at pharmacological modification.
2001 Sep-Oct
Tramadol and acetaminophen tablets for dental pain.
2001 Summer
How to taper tramadol dose.
2002 Feb
New, non-NSAID alternative.
2002 Feb
Randomized clinical trial of Ligasure versus open haemorrhoidectomy.
2002 Feb
Combination analgesic efficacy: individual patient data meta-analysis of single-dose oral tramadol plus acetaminophen in acute postoperative pain.
2002 Feb
Pharmacological treatment of postoperative shivering: a quantitative systematic review of randomized controlled trials.
2002 Feb
The role of tricyclic antidepressants and tramadol in palliative care.
2002 Feb
In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol.
2002 Feb
Stereoselectivity in renal clearance of trans-tramadol and its active metabolite, trans-O-demethyltramadol.
2002 Jan
Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation.
2002 Jan
Use of nonopioid analgesics and adjunctive agents in the management of pain in rheumatic diseases.
2002 Jan
A systematic review of adjuncts for intravenous regional anesthesia for surgical procedures.
2002 Jan
Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.
2002 Jan
Monocomponent chemoembolization in oral and oropharyngeal cancer using an aqueous crystal suspension of cisplatin.
2002 Jan 21
Patient reporting of potential adverse drug reactions: a methodological study.
2002 Mar
Tramadol has no effect on cortical renal blood flow--despite increased serum catecholamine levels--in anesthetized rats: implications for analgesia in renal insufficiency.
2002 Mar
Tramadol infusion for postthoracotomy pain relief: a placebo-controlled comparison with epidural morphine.
2002 Mar
Patents

Sample Use Guides

Chronic: 25 mg PO every morning initially; increased by 25-50 mg/day every 3 days up to 50-100 mg PO q4-6hr PRN; not to exceed 400 mg/day Acute: 50-100 mg PO q4-6hr PRN; not to exceed 400 mg/day
Route of Administration: Oral
A malignancy of A549 and PC-9 cells was detected after treatment of 2 μM tramadol for different time (0, 7, 14, or 28 d). The effect of tramadol on the invasion of A549 and PC-9 cells was performed using transwell chambers (6.5 mm diameter and 8 μm pore size; Millipore, Billerica, MA, USA). After treated with 2 μM tramadol for various time, cells were plated onto the Matrigel-coated upper part of the transwell chamber, fetal bovine serum (FBS) medium (20%) was added to the lower wells as a chemoattractant. 48 hours later, non-invading cells were removed, the invaded cells were fixed with 4% paraformaldehyde for 30 min and stained with 1% crystal violet for 30 min. The number of stained cells on the undersurface of the polycarbonate membranes was then counted visually in five random image fields at 200 × magnifications using a microscope (Olympus, Lake Success, NY, USA).
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:49:23 UTC 2021
Edited
by admin
on Sat Jun 26 02:49:23 UTC 2021
Record UNII
0NG5TTM63P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRAMADOL, (+)-
Common Name English
(+)-(R,R)-TRAMADOL
Common Name English
(1R,2R)-2-((DIMETHYLAMINO)METHYL)-1-(3-METHOXYPHENYL)CYCLOHEXANOL
Common Name English
(+)-TRAMADOL
Common Name English
Code System Code Type Description
PUBCHEM
33741
Created by admin on Sat Jun 26 02:49:23 UTC 2021 , Edited by admin on Sat Jun 26 02:49:23 UTC 2021
PRIMARY
CAS
123154-38-1
Created by admin on Sat Jun 26 02:49:23 UTC 2021 , Edited by admin on Sat Jun 26 02:49:23 UTC 2021
PRIMARY
FDA UNII
0NG5TTM63P
Created by admin on Sat Jun 26 02:49:23 UTC 2021 , Edited by admin on Sat Jun 26 02:49:23 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
TARGET -> INHIBITOR
ENANTIOMER -> ENANTIOMER
RACEMATE -> ENANTIOMER
Agonist of the ?. opioid receptor and inhibits serotonin reuptake.